Godavari Drugs Ltd
Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates[1]
- Market Cap ₹ 65.7 Cr.
- Current Price ₹ 87.2
- High / Low ₹ 134 / 78.9
- Stock P/E 17.3
- Book Value ₹ 57.6
- Dividend Yield 0.00 %
- ROCE 10.1 %
- ROE 10.6 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 14.3 days to 10.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 3.44% over past five years.
- Company has a low return on equity of 12.5% over last 3 years.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -4.31%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | 55 | 71 | 76 | 64 | 84 | 96 | 123 | 161 | 160 | 157 | 113 | 105 | |
| 8 | 49 | 67 | 70 | 60 | 78 | 90 | 113 | 150 | 150 | 143 | 102 | 93 | |
| Operating Profit | 2 | 6 | 4 | 5 | 4 | 5 | 6 | 10 | 11 | 10 | 13 | 12 | 11 | 
| OPM % | 20% | 11% | 6% | 7% | 6% | 7% | 6% | 8% | 7% | 6% | 8% | 10% | 11% | 
| 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | |
| Interest | 0 | 1 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 4 | 
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 
| Profit before tax | 1 | 5 | 2 | 3 | 1 | 2 | 2 | 6 | 7 | 5 | 7 | 6 | 5 | 
| Tax % | -121% | 23% | 38% | 33% | 37% | 31% | 13% | 28% | 25% | 23% | 20% | 22% | |
| 2 | 4 | 1 | 2 | 1 | 1 | 2 | 4 | 5 | 4 | 6 | 4 | 4 | |
| EPS in Rs | 2.06 | 4.85 | 1.79 | 2.40 | 1.10 | 1.61 | 2.66 | 5.48 | 6.97 | 5.03 | 7.37 | 5.82 | 5.03 | 
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% | 
| 5 Years: | 3% | 
| 3 Years: | -11% | 
| TTM: | -32% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% | 
| 5 Years: | 17% | 
| 3 Years: | -6% | 
| TTM: | -41% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% | 
| 5 Years: | 19% | 
| 3 Years: | 9% | 
| 1 Year: | -29% | 
| Return on Equity | |
|---|---|
| 10 Years: | 13% | 
| 5 Years: | 15% | 
| 3 Years: | 12% | 
| Last Year: | 11% | 
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 
| Reserves | 2 | 6 | 7 | 9 | 10 | 11 | 13 | 17 | 22 | 26 | 31 | 36 | 
| 2 | 8 | 16 | 16 | 19 | 22 | 28 | 30 | 23 | 36 | 58 | 64 | |
| 3 | 13 | 21 | 24 | 27 | 33 | 36 | 36 | 49 | 52 | 38 | 35 | |
| Total Liabilities | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 
| 8 | 7 | 9 | 13 | 15 | 15 | 14 | 22 | 26 | 25 | 27 | 33 | |
| CWIP | 0 | 0 | 1 | 0 | 1 | 2 | 9 | 1 | 0 | 9 | 18 | 30 | 
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 
| 7 | 27 | 41 | 43 | 47 | 57 | 61 | 68 | 75 | 87 | 90 | 81 | |
| Total Assets | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | -6 | -5 | 5 | 4 | 4 | 6 | 1 | 11 | 13 | 18 | 11 | |
| -2 | -0 | -2 | -3 | -3 | -2 | -7 | -1 | -5 | -9 | -13 | -20 | |
| 0 | 6 | 7 | -2 | -0 | -1 | 0 | 0 | -6 | -4 | -6 | 8 | |
| Net Cash Flow | -0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | 1 | 1 | -0 | -0 | 
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 87 | 126 | 117 | 152 | 148 | 137 | 134 | 126 | 132 | 138 | 136 | 
| Inventory Days | 973 | 84 | 67 | 70 | 100 | 93 | 84 | 55 | 28 | 57 | 62 | 125 | 
| Days Payable | 179 | 79 | 108 | 124 | 171 | 171 | 144 | 112 | 121 | 132 | 96 | 128 | 
| Cash Conversion Cycle | 814 | 92 | 85 | 63 | 81 | 70 | 78 | 78 | 33 | 58 | 105 | 133 | 
| Working Capital Days | 120 | 63 | 44 | 40 | 47 | 38 | 31 | 46 | 32 | 23 | 9 | 11 | 
| ROCE % | 8% | 32% | 16% | 17% | 11% | 12% | 12% | 18% | 18% | 14% | 14% | 10% | 
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Oct
- 
        
          Scrutinizer''''s Report
          
            29 Sep - 37th AGM (27 Sep 2025): six resolutions passed; authorised capital raised to Rs20 crore; Shilpa Bung appointed.
- 
        
          Announcement under Regulation 30 (LODR)-Change in Management
          
            29 Sep - Shilpa Bung appointed independent director (5-year term from 29.05.2025); VSS & Associates appointed secretarial auditors FY2025-26 to FY2029-30.
- 
        
          Shareholder Meeting / Postal Ballot-Outcome of AGM
          
            27 Sep - AGM adopted FY2024-25 financials; reappointed Mukund Kakani; appointed Shilpa Bung; increased authorised capital to ₹20 crore.
- Closure of Trading Window 19 Sep
Annual reports
- 
    
      Financial Year 2025
      from bse
- 
    
      Financial Year 2024
      from bse
- 
    
      Financial Year 2023
      from bse
- 
    
      Financial Year 2022
      from bse
- 
    
      Financial Year 2021
      from bse
- 
    
      Financial Year 2020
      from bse
- 
    
      Financial Year 2019
      from bse
- 
    
      Financial Year 2018
      from bse
- 
    
      Financial Year 2017
      from bse
- 
    
      Financial Year 2016
      from bse
- 
    
      Financial Year 2015
      from bse
- 
    
      Financial Year 2014
      from bse
- 
    
      Financial Year 2013
      from bse
- 
    
      Financial Year 2012
      from bse
- 
    
      Financial Year 2011
      from bse
Business Overview:[1]
Company is in the business of Manufacturing APIs, drug intermediaries, and fine chemicals and caters to the global Life Science Industry. It has an active Loan License and Contract Manufacturing tie-ups with multinational companies for APIs and drug intermediates